[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574058":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":42,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Experimental: 68Ga-NK224 PET\u002FCT",null,"Each participant receives a single intravenous injection of 68Ga-NK224, and undergo PET\u002FCT imaging within the specified time.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Liang Zhao","CONTACT","86 0592-213-7366","wzhaoliang01@163.com",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":27,"coordinates":28},"Point",[29,30],118.08187,24.47979,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100574058","68ga-nk224-pet-imaging-of-pd-l1-expression-in-cancers-100574058",false,"NCT06754345","68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);\n* (iii) patients who had scheduled 68Ga-NK224 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","90 Years",{"count":47,"type":48},100,"ESTIMATED","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the evaluation of PD-L1 expression in primary and\u002For metastatic tumors, compared with histopathological results.",[52,53],"Tumor","PD-L1",[52,53,55,56],"PET\u002FCT","diagnosis","2026-05-13",{"date":59,"type":60},"2026-05-15","ACTUAL",{"date":62,"type":60},"2023-05-30",{"date":64,"type":48},"2026-11-30",{"name":5,"class":6},1]